The """"""""In Vitro Antiviral Screen for Hepadnaviruses"""""""" Contract is an endeavor by the Hepatitis Program of the Division of Microbiology and Infectious Diseases, NIAID, to facilitate investigators in their pursuit of identifying agents/compounds capable of ameliorating/curing hepatitis R chronic infection. The goal is to identify drugs to rescue the over 300 million chronic carriers of hepatitis B in the world--one million in the U.S. alone--from the progressive, debilitating illness caused by the virus. As an integral part of DMID's preclinical antiviral drug development, the antiviral screen has already met with a high degree of success. Drugs selected by Program staff for entry to the screening process are evaluated for their ability to inhibit the virus, toxicity to cells, and for some compounds preliminary determination of mechanism-of-action in a tissue culture model. If suitable they are recommended for further in vivo studies in the woodchuck animal model funded by separate NIAID contracts. This contract is a vehicle for screening and selection of compounds generated by university-based investigators and small businesses who do not have such in-house capabilities and expertise.

Project Start
1993-10-16
Project End
1998-10-15
Budget Start
1993-10-16
Budget End
1994-10-15
Support Year
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Georgetown University
Department
Microbiology/Immun/Virology
Type
Schools of Dentistry
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Sood, Ramesh K; Bhadti, Vishweshwar S; Fattom, Ali I et al. (2002) Novel ring-expanded nucleoside analogs exhibit potent and selective inhibition of hepatitis B virus replication in cultured human hepatoblastoma cells. Antiviral Res 53:159-64
Chu, C K; Boudinot, F D; Peek, S F et al. (1998) Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antivir Ther 3:113-21
Seley, K L; Schneller, S W; De Clercq, E et al. (1998) The importance of the 4'-hydroxyl hydrogen for the anti-trypanosomal and antiviral properties of (+)-5'-noraristeromycin and two 7-deaza analogues. Bioorg Med Chem 6:797-801
Zembower, D E; Lin, Y M; Flavin, M T et al. (1998) Robustaflavone, a potential non-nucleoside anti-hepatitis B agent. Antiviral Res 39:81-8
Hostetler, K Y; Beadle, J R; Kini, G D et al. (1997) Enhanced oral absorption and antiviral activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, in vitro. Biochem Pharmacol 53:1815-22
Korba, B A; Xie, H; Wright, K N et al. (1996) Liver-targeted antiviral nucleosides: enhanced antiviral activity of phosphatidyl-dideoxyguanosine versus dideoxyguanosine in woodchuck hepatitis virus infection in vivo. Hepatology 23:958-63
Korba, B E (1996) In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res 29:49-51
Korba, B E; Boyd, M R (1996) Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother 40:1282-4